Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lantern Pharma Q3 2026 Results: Turns Profitable, Net Income $697K

Lantern Pharma Inc. reported its third quarter 2026 results, highlighting the formation of Open Medicine AI Inc. as a wholly-owned subsidiary to commercialize its multi-agent AI co-scientist platform. The company disclosed substantial doubt regarding its ability to continue as a going concern without additional funding to support its preclinical and clinical drug development programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income0.7-4.2
EPS (diluted, $ a share)$-0.37$-0.39

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: LTRN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lantern Pharma Inc.: key numbers

Share price
$0.3650Close, Nov 17
Market cap
$5.8M
Shares outstanding
15.89MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lantern Pharma Inc.

All →
4:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Lantern Pharma Nasdaq/NYSE Compliance Notice

Lantern Pharma Inc. received a deficiency notice from Nasdaq on September 25, 2026, for failing to maintain a minimum market value of listed securities (MVLS) of $35 million for 30 consecutive business days. The company has 180 calendar days, or until March 24, 2027, to regain compliance by maintaining an MVLS of at least $35 million for 10 consecutive business days.

Counterparty
Nasdaq
Term
180 days
4:05 PM ET 8-K
Capital Raise

Lantern Pharma Capital Raise of $4M

Lantern Pharma Inc. entered into a securities purchase agreement for a registered direct offering of 1,469,725 common shares and 2,200,000 pre-funded warrants at $1.09 per share. The offering raised approximately $4 million in gross proceeds, with a concurrent private placement of warrants that could provide an additional $4 million if fully exercised. The company intends to use the proceeds for working capital and general corporate purposes.

Value
$4M
Counterparty
institutional investor
6:02 AM ET 8-K
Investor Presentation

Lantern Pharma Investor Presentation

Lantern Pharma hosted a live webinar and filed a formal presentation deck (Exhibit 99.1) to discuss its Open-Medicine AI multi-agentic platform for drug development. The presentation highlights the company's AI-driven approach to drug discovery and development, specifically focusing on the Open-Medicine AI platform.

7:46 AM ET 8-K
Investor Presentation

Lantern Pharma Investor Presentation

Lantern Pharma is hosting a live webinar and investor presentation to discuss the growth plan, development roadmap, and economics of its wholly owned subsidiary, Open-Medicine AI. The session will include a live demonstration of the multi-agentic AI platform's capabilities and an overview of the subscription and enterprise licensing model.

Earnings call
Sep 23, 2026, 12:30 PM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.